debrisoquin has been researched along with Bladder Diseases in 1 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brynne, N | 1 |
| Böttiger, Y | 1 |
| Hallén, B | 1 |
| Bertilsson, L | 1 |
1 trial available for debrisoquin and Bladder Diseases
| Article | Year |
|---|---|
Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
Topics: Adult; Anti-Ulcer Agents; Antihypertensive Agents; Benzhydryl Compounds; Caffeine; Central Nervous S | 1999 |